| Dorothy Kominos & Paul Cox |
Development of Aniline amides Containing Alternative Cores as Orally Active P38 MAP kinase Inhibitors
Katerina Leftheris, John Hynes, Jr., Alaric Dyckman, Tianle Li, Shuqun Lin, Stephen T. Wrobleski, Hong Wu, Rosemary Zhang, Kathleen M. Gillooly, Derek Loo, Kim W. McIntyre, Sidney Pitt, Ding Ren Shen, David J Shuster, Arthur Doweyko, John Sack, Joel Barrish, John Dodd and Gary L. Schieven, Bristol-Myers Squipp, Princeton, NJ |
Inhibitors of mitogen-activated protein (MAP) kinases synthesized by parallel solution- and solid-phase methods
Jeremy Green, Vertex Pharmaceuticals, Cambridge, MA |
Design, Synthesis and SAR of Pyrimidopyrimidines, Dual KDR/FGFR TyrosineKinase Inhibitors
Pamela Rossman, Hoffmann-La Roche, Nutley, NJ |
Coffee Break |
Discovery of BMS-354825, a dual Src/Abl kinase inhibitor with potent anti-tumor activity in preclinical assays
Louis J. Lombardo, Francis Y. Lee, Ping Chen, Derek Norris, Joel C. Barrish, Kamelia Behnia, Amy Camuso, Stephen Castaneda, Lyndon A. M. Cornelius, Jag Das, Arthur M. Doweyko, Krista Fager, Christine Flefleh, Craig Fairchild, John T. Hunt, Ivan Inigo, Kathy A. Johnston, Amrita Kamath, David Kan, Herbert Klei, Roger Luo, Punit Marathe, Suhong Pang, Russell Peterson, Sidney Pitt, Gary L. Schieven, Robert J. Schmidt, John Tokarski, Mei-Li Wen, Robert Wild, John Wityak and Robert M. Borzilleri, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ |
Discovery of novel p38 MAP kinase inhibitors:
Gulzar Ahmed, Pharmacopeia Drug Discovery Inc., Princeton, NJ |